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IMPORTANCE Three years of adjuvant imatinib mesylate therapy is associated with reduced
recurrence rates and improved overall survival in patients with high-risk primary
gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of
treatment. The impact of a longer duration of therapy is unknown.
OBJECTIVE To determine whether adjuvant treatment for primary GIST with imatinib for
5 years is tolerable and efficacious.
DESIGN, SETTING, ANDPARTICIPANTS This prospective, single-arm,phase2 clinical trial
(Postresection Evaluation of Recurrence-free Survival for Gastrointestinal Stromal TumorsWith
5Years of Adjuvant Imatinib [PERSIST-5]) included adult patientswith primaryGIST (expressing
KIT) at 21US institutionswhounderwent amacroscopically complete resection andwere at
intermediate or high risk of recurrence, defined as primaryGIST at any sitemeasuring 2 cmor
largerwith 5 ormoremitoses per 50high-power field or nongastric primaryGISTmeasuring
5 cmor larger. Datawere collected fromAugust 5, 2009, throughDecember 20, 2016.
INTERVENTIONS Imatinib, 400mg once daily, orally for 5 years or until discontinuation of
therapy because of progression or intolerance.
MAIN OUTCOMES ANDMEASURES The primary end point was recurrence-free survival (RFS).
The secondary end point was overall survival.
RESULTS Of the 91 patients enrolled, 48 (53%) weremenwith a median age of 60 years
(range, 30-90 years). Median tumor size was 6.5 cm (range, 2.3-30.0 cm). Median treatment
duration was 55.1 months (range, 0.5-60.6months); 46 patients (51%) completed 5 years of
imatinib therapy. Estimated 5-year RFS was 90% (95% CI, 80%-95%), and overall survival
was 95% (95% CI, 86%-99%). Recurrence was noted in 7 patients: 1 had disease recur
while receiving imatinib (PDGFRAD842Vmutation) and died; 6 had disease recur after
discontinuation of imatinib therapy. Two additional deaths were unrelated to treatment or
tumor progression. Forty-five patients (49%) stopped treatment early because of patient
choice (10 [21%]), adverse events (15 [16%]), or other (11 [12%]). All 91 patients experienced
at least 1 adverse event, and 17 (19%) experienced grade 3 or 4 adverse events.
CONCLUSIONS AND RELEVANCE In this first adjuvant trial, to our knowledge, of patients
with resected primary GIST who received 5 years of imatinib therapy, no patient with
imatinib-sensitive mutations had disease recur during therapy. For patients in whom disease
recurred, recurrence was within 2 years of discontinuation of imatinib therapy. Approximately
half of the patients discontinued treatment early, most commonly because of patient choice,
thus emphasizing the importance of close clinical monitoring to continue imatinib treatment
for patients at appropriate risk.
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G astrointestinal stromal tumor (GIST) is themost com-monmesenchymal tumorof thegastrointestinal tract,with an incidence of 3000 to 5000 cases per year in
the United States.1,2 Approximately 80% of GIST harbor acti-
vatingmutations in theKITproto-oncogene (164920), encod-
ing the KIT receptor tyrosine kinase; 3% to 5% have muta-
tions in PDGFRA (173490), encoding platelet-derived growth
factor receptor α.3 Historically, patients with localized, pri-
mary GIST undergoing macroscopically complete R0/R1 re-
sections (R0,macroscopically completewith negativemicro-
scopic margins; R1, macroscopically complete with positive
microscopicmargins) in thepre-imatinib era hadhigh rates of
recurrenceanda5-yeardisease-specific survival of 54%.4 Sev-
eral risk-stratification models have been developed to pre-
dict the risk of recurrence after R0/R1 resection.5-9
Three phase 3 trials have evaluated the utility of adjuvant
imatinib mesylate for 1, 2, and 3 years in patients with R0/R1
resections.10-13 These studiesdemonstrated that adjuvant ima-
tinib treatment improved recurrence-free survival (RFS) com-
pared with control (placebo in the 1-year American College of
Surgeons Oncology Group [ACOSOG] Z9001 study,10 observa-
tioninthe2-yearEuropeanOrganizationforResearchandTreat-
ment of Cancer [EORTC] 62024 study,12 and 1 year of adjuvant
imatinib therapy in the 3-year Scandinavian Sarcoma Group
[SSG]XVIII/Arbeitsgemeinschaft InternistischeOnkologie [AIO]
study13).Furthermore,SSGXVIII/AIOreported improvement in
overall survival (OS)with 3 years of adjuvant imatinib therapy.
Disease eventually recurred in a similar proportion of patients
after adjuvant therapywas discontinued,with the slope of the
RFS curve after treatment cessation in the experimental arms
resembling those for the control arms.
Thus, adjuvant imatinib therapy of any duration appears
to delay recurrence of GIST and, in a subset of patients, may
improvesurvival.However, it isunclearwhetherextendingex-
posure to imatinib beyond 3 years will further delay recur-
rence by shifting the RFS curve or biologically impacting the
disease to prevent recurrences and decrease the slope of
the RFS curve for high-risk patients. The phase 2 multi-
institutional PostresectionEvaluationofRecurrence-free Sur-
vival for Gastrointestinal Stromal TumorsWith 5 Years of Ad-
juvant Imatinib (PERSIST-5) trialwas conducted todetermine
the long-termefficacy, safety, and tolerability of 5 years of ad-
juvant imatinib treatment inpatientswith intermediateorhigh
riskof recurrenceafter resectionofprimaryGIST (the trial pro-
tocol is available in Supplement 1).
Methods
Patients
Eligiblepatientswereadults (aged≥18years)withprimaryGIST
(basedoncentralpathologyreview)expressingKIT(CD117,con-
firmed by immunohistochemistry) who underwent a macro-
scopically complete resectionwithin 12 weeks before the ini-
tiationof imatinib therapy.AllpatientshadEasternCooperative
Oncology Group performance status of 0 (able to perform ac-
tivitieswithout restriction)or 1 (restricted inphysically strenu-
ous activity but able to perform light work) and adequate he-
patic, renal, and bone marrow function. All patients had
intermediateorhighriskof recurrence,definedasprimaryGIST
at any site, 2 cm or larger with 5 ormoremitoses per 50 high-
power field or nongastric primary GIST measuring 5 cm or
larger.7 The studywas conducted following the approval of lo-
cal institutional reviewboards (eMethods inSupplement2)and
in accordance with Good Clinical Practice guidelines and the
Declaration of Helsinki 2008.14 Eligible patients who elected
to participate in the study provided written informed con-
sent fromafterundergoing resectionof their primaryGISTand
their data were deidentified.
Patients were excluded if they had metastatic and/or re-
current GIST, received previous treatment for GIST except for
previous adjuvant imatinib therapy lasting8weeksor less, re-
ceived previous treatment with other investigational agents
within28daysof the study treatment, hadNewYorkHeartAs-
sociation class III or IV disease, had severe and/or uncon-
trolled concurrent disease, had a known diagnosis of HIV in-
fection, or received concurrent warfarin treatment.
Study Design
The PERSIST-5 trial was a phase 2, single-arm, nonrandom-
ized, open-label trial conductedat 21 institutions in theUnited
States. All enrolled patients received imatinib, 400 mg once
daily. Dose adjustmentswere permitted for intolerance of the
medication.Nodose reductionswereperformed for grade 1 or
2 hematologic or grade 1 nonhematologic toxic effects.
The first patient was enrolled on August 5, 2009, and the
final patient completed 5 years of treatment onMay 18, 2016.
Patients were followed up every 2 weeks for the first month
after registration, every 4months for the first 3 years, and ev-
ery 6 months for years 4 and 5. The original plan for a 2-year
follow-upwas cancelledby the sponsor (Novartis Pharmaceu-
ticals Corporation).
Assessments
Imatinib dosage and compliance, Eastern CooperativeOncol-
ogy Group performance status, and the presence of adverse
events (AEs)were assessed at eachvisit. Surveillance imaging
with abdominal/pelvic computed tomography with oral and
intravenous contrast enhancement or magnetic resonance
Key Points
Question What is the tolerability and efficacy of 5 years of
adjuvant imatinib mesylate therapy in patients with resected
primary gastrointestinal stromal tumor?
Findings In this phase 2 study of 91 adults, no patient with
resected imatinib-sensitive primary gastrointestinal stromal tumor
who received 5 years of adjuvant therapy had disease recur while
receiving imatinib. However, rates of early discontinuation of
imatinib were high (49%).
Meaning Longer-duration adjuvant imatinib may be efficacious
in appropriately selected patients with resected primary
gastrointestinal stromal tumor, but adherence to the planned
course of therapymay be challenging despite its benefits.
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imaging with intravenous contrast enhancement (for pa-
tients with an allergy to computed tomography contrast ma-
terial) was obtained at baseline and at each protocol visit (±14
days) after the first month of receiving treatment. Each type
of radiographic imaging was performed with section thick-
ness of 10 mm or less. For each patient, the same technique
and method of assessment were generally used for each sur-
veillance scan, and laboratory data were collected at desig-
nated time points throughout the study.
Imatinibpharmacokineticassessmentwas initiallyplanned
on day 29 and atmonths 4, 12, 24, 36, and 48; this assessment
was discontinued after August 31, 2011, by protocol amend-
ment.Pharmacokineticswereanalyzedconsideringdataonday
29 and atmonths 4 and 12. Plasma imatinib concentrationwas
determined using a validated liquid chromatography–tandem
massspectrometryassay (TDMPharmaceuticalResearch,LLC).
Quality of life (QoL)was assessedusing theFunctional Assess-
ment of Cancer Therapy–General15 questionnaire completed
by thepatient at baseline andat eachvisit after the firstmonth
while enrolled in the study. Adverse events were graded ac-
cording to the Common Terminology Criteria for Adverse
Events, version 4.03.16 Treatment-emergent AEs were de-
fined as all new or worsening events collected from the date
of the first dose until 30 days after the last dose of imatinib.
PresenceofKITandPDGFRAmutations inprimary tumorswas
determinedaspreviouslydescribed.17Datawerecollected from
August 5, 2009, through December 20, 2016.
Statistical Analysis
Theprimaryendpointof thisstudywasRFS,definedasthetime
fromthedateof the first doseof imatinib to thedateof the first
documented disease recurrence (by radiographic imaging) or
death (fromany cause). Pathologic confirmationof recurrence
was not required. Patients who were alive and without recur-
rence were censored at the last assessment. Secondary end
pointswereOS, safety, and tolerability.Overall survivalwasde-
fined as the time from the date of the first dose of imatinib to
the date of death (from any cause). Exploratory end points in-
cluded QoL assessment, pharmacokinetics, and the associa-
tion betweenmutation status and outcomes. The RFS and OS
were calculated using the Kaplan-Meier method. Cox propor-
tional hazardsmodel analysis was performed to assess the as-
sociations of appropriate covariates. Pharmacokinetic trough
concentrationsweresummarizedbydescriptivestatistics(mean,
SD, andcoefficientofvariation).TheFunctionalAssessmentof
Cancer Therapy–General QoL index total score (sum of social,
physical, functional, and emotional subscales) was summa-
rizedbyvisit; changefrombaselinescoreswassummarized.Sta-
tistical significancewasbasedona2-sidedtestwithP ≤ .05.Sta-
tistical analysiswasprovidedbyUnitedBioSourceCorporation.
Sample sizewas based on the assumption that 5-year RFS
would be at least 80%. To test the null hypothesis of 65%RFS
at 5 years (observed in ACOSOG Z9001)10 against the alterna-
tive hypothesis of 80% RFS with a 1-sided significance level
of 5% (exponential maximum likelihood estimation test)
and 80% power,18 51 evaluable patients (20 events) were re-
quired. To allow for a 40% discontinuation rate, 85 patients
were required (planned enrollment). Even though the actual
discontinuation rate was higher than anticipated, enrolling
91 patients maintained at least 80% power, given the higher
90% RFS against the null hypothesis of 65% RFS.
Results
Of 113 patients screened for the study, 91 (48 [53%] male and
43 [47%] female; median age 60 years [range, 30-90 years])
were enrolled (22 failed screening) (Figure 1) and received at
least 1 dose of imatinib. Patient demographics, tumor fea-
tures, and treatment details are summarized in eTable 1 in
Supplement 2. Risk of recurrence was intermediate in 24 pa-
tients (26%) and high in 67 (74%) based on theMiettinen and
Lasota classification.19Median time fromdiagnosis to the first
dose of imatinib was 10.3 weeks (range, 3.1-23.9 weeks) and
fromsurgery to the first doseof imatinibwas9.6weeks (range,
3.1-12.3 weeks). Six patients (7%) received previous adjuvant
imatinib therapy for amedian of 21.5 days (range, 9-29 days).
Of 85 patients who agreed to biomarker assessment, KIT
or PDGFRA mutations were identified at baseline in 73 pa-
tients (86%) (eTable 2 in Supplement 2).
Efficacy
Forty-six patients completed the study treatment, including
19whocontinued imatinib therapyafter study completion.Of
91 patients who enrolled, 79 (87%) agreed to follow-up, and
68 (75%) completed follow-up after treatment. With median
Figure 1. Trial FlowDiagram
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treatment duration of 55.1 months (range, 0.5-60.6 months)
andmedian follow-up after treatment of 19.6months (range,
4.6-32.1 months), the 5-year RFS was 90% (95% CI, 80%-
95%) (Figure 2A). Of the 91 patients, 7 (8%) developed recur-
rent disease, including 1 patientwhosedisease recurredwhile
receiving imatinib 11.5 months into therapy and 6 patients
whose disease recurred from 7.4 to 23.1 months after discon-
tinuing imatinib therapy (Figure2BandeTable3 inSupplement
2). Thepatientwhohad recurrentdiseasewhile receiving ima-
tinib had a PDGFRA D842V mutation and was the only pa-
tient in this study who died of progressive disease. The 6 pa-
tients whose disease recurred had discontinued imatinib
treatment before recurrencebecauseof patient choice (n = 3),
AEs (n = 2), or completion of 5 years of treatment (n = 1).
Five of the 6 patients had imatinib-insensitive mutations
(PDGFRA exon 18/D842V), KIT exon 9 mutations, or no KIT
or PDGFRAmutations at baseline. Age, sex, baseline Eastern
Cooperative Oncology Group performance status, and loca-
tion of primary lesion were not associated with RFS.
The 5-year OSwas 95% (95%CI, 86%-99%) (Figure 2C). Of
the 3 patients who died, only the patient with a PDGFRAmu-
tationwhose disease recurredwhile receiving imatinib died of
Figure 2. Efficacy of Imatinib Therapy
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progressive disease. The other 2 patients died of causes unre-
lated to the treatmentor the tumor (eTable 3 inSupplement2);
1patientwasstill receiving imatinibtherapyat thetimeofdeath.
Pharmacokinetics
Pharmacokineticdatawereavailableonly for the first 12months
of treatment since few patients agreed to have trough levels of
imatinibmeasuredsubsequently.For60patientswithavailable
pharmacokinetic data, mean (SD) imatinib trough levels were
1006.2 (685.0) ng/mL (range, 248-4798 ng/mL) (eFigure in
Supplement 2). Levels remained constant during the first 12
months of therapy andwere 33%higher inwomenat 4months
of treatmentandoverall for thefirst 12months.Pharmacokinetic
datawere too limitedtodrawanyassociationwithdrugtoxicity.
Quality of Life
Median QoL scores remained stable between baseline (96.4;
range, 46.0-108.0) and60months (97.5; range, 47.0-108.0) for
patientswhocompletedsurveysandneverdecreasedmorethan
3points frombaseline.Thus,QoLremainedstableat60months
throughout treatment for40patientswhocontinued follow-up
andcompletedsurveys.Surveyswerenotcompletedbypatients
after early discontinuation of treatment, and no associations
betweenQoL and early discontinuation could bemade.
Early Treatment Discontinuation and Safety
Imatinib therapywasdiscontinuedbeforecompletionof5years
in 45 of 91 patients (49%) (Figure 3), of whom 27 (60%) were
women.Reasons for earlydiscontinuationwerepatient choice
(19 [21%]), AEs (15 [17%]), protocol deviation (4 [4%]), loss to
follow-up (3 [3%]), death (2 [2%]), disease recurrence (1 [1%]),
and other (1 [1%]). Most treatment discontinuations occurred
during the first 2 years of treatment. However, discontinua-
tion of treatment because of patient choice occurred at a rela-
tively steady rate throughout the duration of the treatment.
Dose reductions were required in 36 of 91 patients (40%) for
AEs (26 [29%]), laboratory abnormalities (9 [10%]), schedul-
ing or administrative issues (7 [8%]), protocol-mandated
(2 [2%]), and dosing error (1[1%]).
All patients experienced at least 1 AE. Themost common
AEs (any grade) associatedwith study treatmentwere nausea
(56 of 91 [62%]), diarrhea (45 [50%]), fatigue (34 [37%]), peri-
orbitaledema(30[33%]),andmusclespasms(29[32%]) (eTable
4 in Supplement 2). Grade 3 or 4 AEs associated with study
treatmentwere identified in 17 of 91 patients (19%). Themost
common AEs (any grade) regardless of whether there was an
association with the study drug were nausea (65 of 91 [71%]),
diarrhea (57 [63%]), fatigue (45 [50%]), muscle spasms (37
[41%]), vomiting (35 [39%]), and periorbital edema (31 [34%])
(eTable 5 in Supplement 2). Grade 3 or 4 AEs regardless of
whether associatedwith the study drugwere identified in 45
of 91 patients (50%).
Discussion
This is the first study, to our knowledge, to report results
from 5 years of adjuvant imatinib therapy. Long-term ima-
tinib treatment was effective in preventing recurrence of
GIST during the course of treatment for patients with muta-
tions sensitive to this drug. The 5-year estimated RFS was
90%, and the OS rate was 95%. Of the 7 patients who devel-
oped recurrent GIST, disease recurred in 6 patients after dis-
continuation of imatinib treatment. Furthermore, only 1 of 57
patients with an imatinib-sensitive, KIT exon 11 mutation had
a recurrence, and this only occurred after discontinuation of
imatinib treatment. Survival rates were comparable with
those from previous adjuvant trials (eTable 6 in Supplement
2). The EORTC 62024 trial,12 which included intermediate-
and high-risk patients, reported 5-year RFS of 69% in the
2-year arm and 63% in the placebo arm. The SSG XVIII/AIO
trial,13 which included only high-risk patients, reported
5-year RFS of 66% in the 3-year arm and 48% in the 1-year
arm. In the EORTC 62024 study,12 5-year OS was 100%
among the intermediate-risk patients and 99% among the
high-risk patients,12 and in the SSG XVIII/AIO study,13 the
5-year OS was 92% among the immediate-risk patients and
82% among the high-risk patients.
Figure 3. Timing and Reasons for Early Discontinuation of Imatinib Therapy
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A second important finding from this study was that
49%ofpatientsdiscontinued treatmentearlydespite theavail-
ability of the SSG XVIII/AIO study13 reported in 2012 while
PERSIST-5 (current study) was under way. The discontinua-
tion rate was higher than in the 4 previously reported multi-
institutional adjuvant trials (ACOSOG Z9000 1-year trial [17%
discontinuationrate],ACOSOGZ90011-year trial [27%],EORTC
620242-year trial [25%], and SSGXVIII/AIO 3-year trial [26%]
and 1-year trial [13%]).10,12,13,20Much of this difference can be
attributed to a large percentage of patients (21%)who discon-
tinued therapybecauseof patient choice (comparedwith0%-
10% in the other trials).10,12,13,20 The percentages of patients
who discontinued imatinib treatment before the completion
of the trial for other reasons (ie, AEs or disease progression)
were similar to those in the previous trials. To minimize
follow-up burden on patients, the recommended interval for
surveillance imaging was changed for years 4 and 5 from
every 4 months to every 6 months. This was consistent with
the surveillance practice at many institutions.
Data reflecting QoL were stable for those who completed
surveys, but we did not capture data as the study progressed
for patients who stopped treatment early. The data should be
interpreted with caution because of a potential for bias. None
of the other adjuvant imatinib trials reportedQoLdata. There-
fore, it was difficult to knowwhat could have been done to re-
duce thisdropout rate.However, thehighdiscontinuation rate
suggests that critical elements of adjuvant therapy for this dis-
easewereeffective symptommanagementandstrongcommit-
ment fromclinicians toretainpatientsontherapy.Althoughthis
is a relatively well-tolerated drug with proven survival effi-
cacy in the adjuvant setting, retaining patients on therapy af-
ter a curativeoperation is challenging.Womenhadhigher ima-
tinib trough levels, suggesting that lower doses could be
considered.Lowerdosescouldreducediscontinuationratesbe-
cause 60% of patients who discontinued therapy early were
women. However, we could not identify any association be-
tween early discontinuation of imatinib therapy and imatinib
troughlevelsbecauseof limitedavailablepharmacokineticdata.
Because this was a single-arm study, we could not deter-
mine whether 5 years of adjuvant imatinib therapy provided
anysurvivalbenefit comparedwith3yearsofadjuvant therapy.
Nevertheless, theRFS rates are comparablewith those in pre-
vious studies, confirming that imatinib is effective in reduc-
ing the risk of recurrence for patients with sensitive muta-
tions (as opposed to the insensitive PDGFRA exon 18 D842V)
while still receiving imatinib therapy. Long-term follow-up re-
sults (median, 7.5 years) of the 3-year adjuvant SSGXVIII/AIO
study confirmed that the initial benefit of RFS and OS was
sustained.21 Long-term follow-up in thepresent studywill de-
terminewhether recurrence ratesafterdiscontinuationof ima-
tinib therapy are similar to those fromother studies. Further-
more, a randomized trial of 3-year treatment vs 5-year
treatment with imatinib (SSG XXII, NCT 02413736) is under
way. The ACOSOG Z9000 trial demonstrated that recur-
rences were detected 4 years after completion of adjuvant
therapy; thus, ongoing radiographic surveillance is
recommended.20 Because many recurrences were observed
within 2 years of treatment discontinuation, surveillance af-
ter discontinuation may need to be more frequent (for in-
stance, every 3months during the first 2 years after stopping
imatinib therapy) even if surveillance intervalswere longer to-
ward the end of the treatment period.
In patients with metastatic GIST treated with tyrosine ki-
nase inhibitor therapy, secondary resistance may develop be-
causeof aproliferationof tumor cells harboringpreexisting ty-
rosine kinase inhibitor–resistant mutations. With the only
recurrence of GIST on adjuvant therapy occurring in a patient
withan insensitivemutation (PDGFRAexon18D842V),wecan-
not comment on whether such a long duration of therapy re-
sults inacquiredresistance intheadjuvantsetting.Becauseonly
3 targeted therapy agents are currently approved for advanced
disease (imatinib, sunitinibmalate, and regorafenib), it seems
reasonable to consider at least delaying, if not preventing re-
currence,with theuseof adjuvant therapy inpatientswithpri-
mary localized GISTwho are at the greatest risk of recurrence.
Overall, imatinibwaswell tolerated, and the AEs reported
were consistentwith the overall imatinib safety profile. All pa-
tients in this trial and nearly all of the patients in the ACOSOG
Z9001 (95%)andSSGXVIII/AIO(99%)trialsexperiencedat least
1 AE, althoughmost AEs were not severe (grades 3-4).10,11
Limitations
Aweaknessinourstudyisthat26%ofpatientshadintermediate-
risk GIST, a subset of patients for whom the benefit of adju-
vant therapy is debated. The SSG XVIII/AIO study excluded
intermediate-risk patients.13 European Society of Medical
Oncology guidelines currently recommend adjuvant ima-
tinib therapy for patients with a significant risk of relapse,
with “room for shared decision-making when the risk is
intermediate.”22(piii22) The US National Comprehensive Can-
cer Network guidelines for GIST recommend adjuvant ima-
tinib therapy for patients with significant risk of recurrence,
defined as intermediate risk or high risk.23 TheNational Com-
prehensiveCancerNetworkdoesnotparsewhich intermediate-
risk patients should be considered, but it does reference the
SSG XVIII/AIO and ACOSOG Z9001 trials. Furthermore, when
we designed this study,we did not exclude patientswithmu-
tationsnowappreciatedas imatinib insensitive, suchasPDGFR
D842V-, RAF-, PI3K-, NF1-mutant, or succinate dehydroge-
nase–deficient GIST, because data on the association be-
tweenmutation typeandefficacy fromtheprevious trialswere
not available until 2014 (SSG XVIII/AIO) and 2017 (ACOSOG
Z9001).22,24,25 If this trial was designed today, we would ex-
clude patients with PDGFRA exon 18 D842V mutations; this
mutationwas seen in the singlepatient inour studywhosedis-
ease recurred while receiving imatinib and who died of pro-
gressive disease. Finally, we did not alter the 400-mg/d dos-
age for patientswithKIT exon9mutationswho, in the setting
ofmetastaticdisease,benefit froman800-mg/ddosage.When
this trialwasdesigned, theMetaGISTdata26demonstrating the
benefit of the higher imatinib dose were not published, and
therefore, the dosage was uniform across patients with all
mutations.24 It remainsunclearwhetherpatientswithKITexon
9 or PDGFRAmutations would benefit from higher adjuvant
imatinib doses or from adjuvant therapy at all.We cannot de-
termine whether patients with GISTmutations insensitive to
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the standard dose of imatinib had discontinued the therapy
early because of presumed lack of efficacy.
Conclusion
In our trial, 5 years of adjuvant imatinib therapy was safe
and effective at controlling recurrence rates in patients with
imatinib-sensitive mutations while receiving therapy follow-
ing resection of primary GIST. Because of the high early dis-
continuation rate with prolonged therapy, clinician support
of patients receiving imatinib may improve compliance with
their adjuvant regimen. A randomized trial of 3-year therapy
vs 5-year therapy of imatinib that is currently under way will
help determine whether a longer duration of therapy is
superior.
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